- Home
- EML vs DAWN Comparison
EML vs DAWN Comparison
Compare EML & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- DAWN
- Stock Information
- Founded
- EML 1858
- DAWN 2018
- Country
- EML United States
- DAWN United States
- Employees
- EML N/A
- DAWN N/A
- Industry
- EML Industrial Machinery/Components
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- DAWN Health Care
- Exchange
- EML Nasdaq
- DAWN Nasdaq
- Market Cap
- EML 141.7M
- DAWN 658.9M
- IPO Year
- EML N/A
- DAWN 2021
- Fundamental
- Price
- EML $24.00
- DAWN $6.88
- Analyst Decision
- EML
- DAWN Strong Buy
- Analyst Count
- EML 0
- DAWN 7
- Target Price
- EML N/A
- DAWN $31.57
- AVG Volume (30 Days)
- EML 12.2K
- DAWN 1.3M
- Earning Date
- EML 08-05-2025
- DAWN 07-29-2025
- Dividend Yield
- EML 1.83%
- DAWN N/A
- EPS Growth
- EML N/A
- DAWN N/A
- EPS
- EML N/A
- DAWN N/A
- Revenue
- EML $271,440,503.00
- DAWN $161,922,000.00
- Revenue This Year
- EML $1.56
- DAWN $17.98
- Revenue Next Year
- EML $7.00
- DAWN $49.50
- P/E Ratio
- EML $11.25
- DAWN N/A
- Revenue Growth
- EML 8.15
- DAWN N/A
- 52 Week Low
- EML $19.06
- DAWN $6.08
- 52 Week High
- EML $35.03
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- EML 58.59
- DAWN 57.28
- Support Level
- EML $21.78
- DAWN $6.52
- Resistance Level
- EML $23.83
- DAWN $6.95
- Average True Range (ATR)
- EML 0.57
- DAWN 0.25
- MACD
- EML 0.06
- DAWN 0.04
- Stochastic Oscillator
- EML 100.00
- DAWN 90.79
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.